Oligomers comprising activated disulfides which bind to plasma proteins and their use for delivery to cells
View Patent ↗The activated oligomer compounds described herein are capable of forming bio-reversible covalent bonds with plasma proteins, in particular with human serum albumin. The plasma protein-oligomer complexes of the present invention exhibit enhanced cellular entry and significantly enhanced serum half-life.
1. A method of treating a subject with an antisense oligomer, the method comprising:
administering an antisense oligomer to a subject, wherein said antisense oligomer comprises an activated disulfide moiety selected from substituted or unsubstituted dithiopyridyl, substituted or unsubstituted dithiobenzothiazolyl, and substituted or unsubstituted dithiotetrazolyl, said antisense oligomer conjugated optionally with a bivalent linking group to said activated disulfide moiety, and wherein said activated disulfide moiety is capable of forming a disulfide bond with a plasma protein that is stable under plasma conditions and unstable under cellular conditions.
2. The method of claim 1 , wherein the antisense oligomer is selected from an oligonucleotide, a peptide nucleic acid or a morpholino nucleic acid.
3. The method of claim 2 , wherein the antisense oligomer is an oligonucleotide.
4. The method of claim 3 , wherein the oligonucleotide comprises at least one 2′-modified nucleotide, wherein said 2′-modification is selected from halogen, alkoxy, substituted alkoxy, amino, or substituted amino.
5. The method of claim 3 , wherein the oligonucleotide comprises at least one phosphorothioate internucleoside linkage.
6. The method of claim 3 , wherein the oligonucleotide comprises at least one phosphodiester internucleoside linkage.
7. The method of claim 2 , wherein the antisense oligomer is a peptide nucleic acid.
8. The method of claim 2 , wherein the antisense oligomer is a double-stranded oligonucleotide.
9. The method of claim 8 , wherein the double-stranded oligonucleotide comprises a first strand and a second strand.
10. The method of claim 9 , wherein at least one nucleotide of the first or the second strand of the double-stranded oligonucleotide is 2′-modified nucleotide, wherein said 2′ modification is selected from halogen, alkoxy, substituted alkoxy, amino, or substituted amino.
11. The method of claim 9 , wherein at least one internucleoside linkage of the first or the second strand of the double-stranded oligonucleotide is a phophorothioate.
12. The method of claim 9 , wherein at least one internucleoside linkage of the first or the second strand of the double-stranded oligonucleotide is a phosphodiester.
13. The method of claim 1 , wherein said activated disulfide moiety comprises 2-pyridyl; 3-nitro-2-pyridyl, 5-nitro-2-pyridyl, 2-benzothiazolyl, N—(C 1 -C 12 alkyl)-2-pyridyl, N-oxide-2-pyridyl, or 1-methyl-2-1H-tetrazolyl.
14. The method of claim 1 , wherein the bivalent linking group is a bivalent substituted or unsubstituted aliphatic group.
15. The method of claim 1 , wherein the bivalent linking group is of the formula:
-Q 1 -G-Q 2 -, wherein
Q 1 and Q 2 are independently absent or selected from substituted or unsubstituted C 1 -C 12 alkylene, substituted or unsubstituted alkarylene or —(CH 2 ) m —O—(CH 2 ) p —, wherein each m and p are, independently, an integer from 1 to about 10;
G is —NH—C(O)—, —C(O)—NH—, —NH—C(O)—NH—, —NH—C(S)—NH—, —NH—O—, NH—C(O)—O—, or —O—CH 2 —C(O)—NH—.
16. The method of claim 14 , wherein the bivalent linking group is selected from:
17. The method of claim 1 , wherein the step of administering is intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion.
18. A method of heating a subject with an antisense oligomer, the method comprising:
selecting an antisense oligomer for forming a bio-reversible bond with a plasma protein in vivo, wherein said antisense oligomer is identified as capable of forming a bio-reversible bond with a plasma protein in vivo based on said antisense oligomer comprising an activated disulfide moiety capable of forming a disulfide bond with a plasma protein that is stable under plasma conditions and unstable under cellular conditions, and wherein said activated disulfide moiety selected from substituted or unsubstituted dithiopyridyl, substituted or unsubstituted dithiobenzothiazolyl, and substituted or unsubstituted dithiotetrazolyl, said antisense oligomer conjugated optionally with a bivalent linking group to said activated disulfide moiety and
administering said antisense oligomer to said subject.